Silverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report)’s stock price was down 1.6% during mid-day trading on Thursday . The company traded as low as $5.66 and last traded at $5.67. 1,353,862 shares traded hands during trading, an increase of 301% from the average daily volume of 337,931 shares. The stock had previously closed at $5.76.
Silverback Therapeutics Stock Down 8.9%
The firm has a market cap of $184.98 million, a price-to-earnings ratio of -2.12 and a beta of 0.60. The company’s 50-day moving average price is $8.23 and its 200-day moving average price is $8.71.
Silverback Therapeutics Company Profile
Silverback Therapeutics, Inc (NASDAQ: SBTX) is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company’s proprietary ImmunoTAC™ (tumor-activated cytokine) platform is designed to harness the innate immune system by conjugating toll-like receptor agonists to tumor-targeting antibodies. This modular approach aims to deliver immune-activating molecules directly to the tumor microenvironment, potentially improving the safety and efficacy profiles of existing immunomodulatory therapies.
Silverback’s pipeline includes multiple antibody-TLR agonist conjugates in early-phase clinical trials, each directed against distinct tumor-associated antigens.
Further Reading
- Five stocks we like better than Silverback Therapeutics
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
- MarketBeat Week in Review – 07/27- 07/31
Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
